CalciMedica (CALC) Cash & Equivalents (2019 - 2026)

CalciMedica (CALC) has 8 years of Cash & Equivalents data on file, last reported at $8.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 34.98% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 34.98% YoY) and the FY2025 annual result came in at $11.5 million, up 45.18% from the prior year.
• Cash & Equivalents declined to $8.2 million in Q1 2026, from $11.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $34.2 million in Q1 2023 to a low of $96000.0 in Q3 2022.
• A 5-year average of $10.1 million and a median of $8.0 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 99.16% — and 2023, when it soared 12029.17%.
• Tracing CALC's Cash & Equivalents over 5 years: stood at $96000.0 in 2022, then soared by 5660.42% to $5.5 million in 2023, then jumped by 43.49% to $7.9 million in 2024, then soared by 45.18% to $11.5 million in 2025, then retreated by 29.13% to $8.2 million in 2026.
• The last three Cash & Equivalents figures came in at $8.2 million (Q1 2026), $11.5 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.